PURPOSE: To determine if hypoxia-related molecular markers are associated with (60)Cu labeled diacetyl-bis (N4 -methylthiosemicarbazone); ((60)Cu-ATSM) imaging of tumor hypoxia in cervical cancer. PROCEDURES: Fifteen patients were enrolled in a prospective study and underwent evaluation of tumor hypoxia with positron emission tomography (PET) using (60)Cu-ATSM. (60)Cu-ATSM-PET imaging was compared with the expression of tissue molecular markers, which included vascular endothelial growth factor (VEGF), cyclo-oxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), carbonic anyhdrase IX (CA-9), and apoptotic index. RESULTS: Six patients had hypoxic tumors determined by (60)Cu-ATSM, and nine had non-hypoxic tumors. The 4-year overall survival estimates were 75% for patients with non-hypoxic tumors and 33% for those with hypoxic tumors (p = 0.04). Overexpression of VEGF (p = 0.13), EGFR (p = 0.05), CA-9 (p = 0.02), COX-2 (p = 0.08), and the presence of apoptosis (p = 0.005) occurred in patients with hypoxic tumors. Cox proportional hazards modeling demonstrated hypoxia as determined by (60)Cu-ATSM to be a significant independent predictor of tumor recurrence (p = 0.0287). CONCLUSIONS: (60)Cu-ATSM hypoxia was correlated with overexpression of VEGF, EGFR, COX-2, CA-9, an increase in apoptosis, and a poor outcome.
PURPOSE: To determine if hypoxia-related molecular markers are associated with (60)Cu labeled diacetyl-bis (N4 -methylthiosemicarbazone); ((60)Cu-ATSM) imaging of tumor hypoxia in cervical cancer. PROCEDURES: Fifteen patients were enrolled in a prospective study and underwent evaluation of tumor hypoxia with positron emission tomography (PET) using (60)Cu-ATSM. (60)Cu-ATSM-PET imaging was compared with the expression of tissue molecular markers, which included vascular endothelial growth factor (VEGF), cyclo-oxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), carbonic anyhdrase IX (CA-9), and apoptotic index. RESULTS: Six patients had hypoxic tumors determined by (60)Cu-ATSM, and nine had non-hypoxic tumors. The 4-year overall survival estimates were 75% for patients with non-hypoxic tumors and 33% for those with hypoxic tumors (p = 0.04). Overexpression of VEGF (p = 0.13), EGFR (p = 0.05), CA-9 (p = 0.02), COX-2 (p = 0.08), and the presence of apoptosis (p = 0.005) occurred in patients with hypoxic tumors. Cox proportional hazards modeling demonstrated hypoxia as determined by (60)Cu-ATSM to be a significant independent predictor of tumor recurrence (p = 0.0287). CONCLUSIONS: (60)Cu-ATSM hypoxia was correlated with overexpression of VEGF, EGFR, COX-2, CA-9, an increase in apoptosis, and a poor outcome.
Authors: J S Rasey; W J Koh; M L Evans; L M Peterson; T K Lewellen; M M Graham; K A Krohn Journal: Int J Radiat Oncol Biol Phys Date: 1996-09-01 Impact factor: 7.038
Authors: C Y Kim; M H Tsai; C Osmanian; T G Graeber; J E Lee; R G Giffard; J A DiPaolo; D M Peehl; A J Giaccia Journal: Cancer Res Date: 1997-10-01 Impact factor: 12.701
Authors: Joseph Waller; Benjamin Onderdonk; Ann Flood; Harold Swartz; Jaffer Shah; Asghar Shah; Bulent Aydogan; Howard Halpern; Yasmin Hasan Journal: Br J Radiol Date: 2020-04-22 Impact factor: 3.039
Authors: Alexander M Spence; Mark Muzi; Kristin R Swanson; Finbarr O'Sullivan; Jason K Rockhill; Joseph G Rajendran; Tom C H Adamsen; Jeanne M Link; Paul E Swanson; Kevin J Yagle; Robert C Rostomily; Daniel L Silbergeld; Kenneth A Krohn Journal: Clin Cancer Res Date: 2008-05-01 Impact factor: 12.531
Authors: Pelin A Ciris; Mukund Balasubramanian; Antonio L Damato; Ravi T Seethamraju; Clare M Tempany-Afdhal; Robert V Mulkern; Akila N Viswanathan Journal: J Magn Reson Imaging Date: 2016-03-12 Impact factor: 4.813